Executive interview – Imugene

Published on 9 March 2017

Imugene is a clinical-stage immuno-oncology company. Its lead product is HER-Vaxx, a B-cell peptide vaccine for the treatment of gastric cancer. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that overexpress the HER-2/neu receptor, such as breast cancer and gastric cancer. HER-Vaxx has successfully completed a Phase I study in breast cancer and has commenced a Phase Ib/II study in gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. Imugene has broadened its pipeline with the acquisition of arginine modulators (small molecules) to develop to preclinical proof of concept.

In this webcast, CEO Leslie Chong provides an overview of Imugene’s technology. She discusses the business model and its current position in the market against its competitors, the exciting developments ahead in the next 12 to 24 months and the latest opportunities for the company.

Share this with friends and colleagues